問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃釧峰

Recruiting

List

56Cases

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

2020-05-01 - 2023-02-22

Phase I/II

A Phase 1b/2a, Open-Label Study to Evalute the Safety, Tolerability and Immunogenicity of VTP-300 with or wuthout Nivoulumab in Participants with Chronic Hepatitis B infecttion

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    ChAdOx1-HBV; MVA-HBV; Nivolumab

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2019-10-01 - 2023-07-17

Phase III

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR)

  • Condition/Disease

    D-LIVR

  • Test Drug

    Lonafarnib

Participate Sites
6Sites

Recruiting6Sites

2019-12-01 - 2022-09-02

Phase II

A randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor (LJN452) & licogliflozin (LIK066) combination therapy and each monotherapy compared with placebo, for treatment of adult participants with nonalcoholic steatohepatitis (NASH) and liver fibrosis (ELIVATE).

  • Condition/Disease

    Non Alcoholic Steatohepatitis (NASH)

  • Test Drug

    LJN452/LIK066

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2022-06-01 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB